FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2157500906> ?p ?o ?g. }

• W2157500906 endingPage "1206" @default.
• W2157500906 startingPage "1200" @default.
• W2157500906 abstract "Bevacizumab has recently been approved by the US Food and Drug Administration for recurrent glioblastoma (GBM). However, patterns of relapse, prognosis, and outcome of further therapy after bevacizumab failure have not been studied systematically.We identified patients at Memorial Sloan-Kettering Cancer Center with recurrent GBM who discontinued bevacizumab because of progressive disease.There were 37 patients (26 men with a median age of 54 years). The most common therapies administered concurrently with bevacizumab were irinotecan (43%) and hypofractionated reirradiation (38%). The median overall survival (OS) after progressive disease on bevacizumab was 4.5 months; 34 patients died. At the time bevacizumab was discontinued for tumor progression, 17 patients (46%) had an increase in the size of enhancement at the initial site of disease (local recurrence), 6 (16%) had a new enhancing lesion outside of the initial site of disease (multifocal), and 13 (35%) had progression of predominantly nonenhancing tumor. Factors associated with shorter OS after discontinuing bevacizumab were lower performance status and nonenhancing pattern of recurrence. Additional salvage chemotherapy after bevacizumab failure was given to 19 patients. The median progression-free survival (PFS) among these 19 patients was 2 months, the median OS was 5.2 months, and the 6-month PFS rate was 0%.Contrast enhanced MRI does not adequately assess disease status during bevacizumab therapy for recurrent glioblastoma (GBM). A nonenhancing tumor pattern of progression is common after treatment with bevacizumab for GBM and is correlated with worse survival. Treatments after bevacizumab failure provide only transient tumor control." @default.
• W2157500906 created "2016-06-24" @default.
• W2157500906 creator A5010536553 @default.
• W2157500906 creator A5012372987 @default.
• W2157500906 creator A5057541817 @default.
• W2157500906 creator A5061674089 @default.
• W2157500906 creator A5065795175 @default.
• W2157500906 creator A5070190752 @default.
• W2157500906 creator A5084965180 @default.
• W2157500906 creator A5087754052 @default.
• W2157500906 date "2009-10-12" @default.
• W2157500906 modified "2023-10-14" @default.
• W2157500906 title "Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma" @default.
• W2157500906 cites W1537447319 @default.
• W2157500906 cites W1858161324 @default.
• W2157500906 cites W1959628099 @default.
• W2157500906 cites W1992812368 @default.
• W2157500906 cites W2000292756 @default.
• W2157500906 cites W2001355942 @default.
• W2157500906 cites W2002727873 @default.
• W2157500906 cites W2017322644 @default.
• W2157500906 cites W2018016372 @default.
• W2157500906 cites W2020021293 @default.
• W2157500906 cites W2025799338 @default.
• W2157500906 cites W2034822725 @default.
• W2157500906 cites W2054169323 @default.
• W2157500906 cites W2063622451 @default.
• W2157500906 cites W2088454377 @default.
• W2157500906 cites W2092409918 @default.
• W2157500906 cites W2093783077 @default.
• W2157500906 cites W2095027624 @default.
• W2157500906 cites W2096287682 @default.
• W2157500906 cites W2103796195 @default.
• W2157500906 cites W2114098415 @default.
• W2157500906 cites W2127745545 @default.
• W2157500906 cites W2130690650 @default.
• W2157500906 cites W2136240869 @default.
• W2157500906 cites W2137582962 @default.
• W2157500906 cites W2137686302 @default.
• W2157500906 cites W2140088548 @default.
• W2157500906 cites W2140201170 @default.
• W2157500906 cites W2142312148 @default.
• W2157500906 cites W2147535764 @default.
• W2157500906 cites W2162352067 @default.
• W2157500906 cites W2162872529 @default.
• W2157500906 cites W2170367762 @default.
• W2157500906 doi "https://doi.org/10.1212/wnl.0b013e3181bc0184" @default.
• W2157500906 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2839807" @default.
• W2157500906 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20385899" @default.
• W2157500906 hasPublicationYear "2009" @default.
• W2157500906 type Work @default.
• W2157500906 sameAs 2157500906 @default.
• W2157500906 citedByCount "275" @default.
• W2157500906 countsByYear W21575009062012 @default.
• W2157500906 countsByYear W21575009062013 @default.
• W2157500906 countsByYear W21575009062014 @default.
• W2157500906 countsByYear W21575009062015 @default.
• W2157500906 countsByYear W21575009062016 @default.
• W2157500906 countsByYear W21575009062017 @default.
• W2157500906 countsByYear W21575009062018 @default.
• W2157500906 countsByYear W21575009062019 @default.
• W2157500906 countsByYear W21575009062020 @default.
• W2157500906 countsByYear W21575009062021 @default.
• W2157500906 countsByYear W21575009062022 @default.
• W2157500906 countsByYear W21575009062023 @default.
• W2157500906 crossrefType "journal-article" @default.
• W2157500906 hasAuthorship W2157500906A5010536553 @default.
• W2157500906 hasAuthorship W2157500906A5012372987 @default.
• W2157500906 hasAuthorship W2157500906A5057541817 @default.
• W2157500906 hasAuthorship W2157500906A5061674089 @default.
• W2157500906 hasAuthorship W2157500906A5065795175 @default.
• W2157500906 hasAuthorship W2157500906A5070190752 @default.
• W2157500906 hasAuthorship W2157500906A5084965180 @default.
• W2157500906 hasAuthorship W2157500906A5087754052 @default.
• W2157500906 hasBestOaLocation W21575009062 @default.
• W2157500906 hasConcept C121608353 @default.
• W2157500906 hasConcept C126322002 @default.
• W2157500906 hasConcept C141071460 @default.
• W2157500906 hasConcept C143998085 @default.
• W2157500906 hasConcept C2776694085 @default.
• W2157500906 hasConcept C2777802072 @default.
• W2157500906 hasConcept C2778822529 @default.
• W2157500906 hasConcept C2779256057 @default.
• W2157500906 hasConcept C2780259306 @default.
• W2157500906 hasConcept C2780739268 @default.
• W2157500906 hasConcept C526805850 @default.
• W2157500906 hasConcept C71924100 @default.
• W2157500906 hasConceptScore W2157500906C121608353 @default.
• W2157500906 hasConceptScore W2157500906C126322002 @default.
• W2157500906 hasConceptScore W2157500906C141071460 @default.
• W2157500906 hasConceptScore W2157500906C143998085 @default.
• W2157500906 hasConceptScore W2157500906C2776694085 @default.
• W2157500906 hasConceptScore W2157500906C2777802072 @default.
• W2157500906 hasConceptScore W2157500906C2778822529 @default.
• W2157500906 hasConceptScore W2157500906C2779256057 @default.
• W2157500906 hasConceptScore W2157500906C2780259306 @default.
• W2157500906 hasConceptScore W2157500906C2780739268 @default.
• W2157500906 hasConceptScore W2157500906C526805850 @default.

• next